About Dianne Sacco, MD

Dianne Sacco is the Director of the Kidney Stone Program at Mass General. She is also on the Board of Directors for the New England Section of the American Urological Association and the Massachusetts Association of Practicing Urologists.

Dianne Sacco was born in Pittsfield, Massachusetts. She completed her medical school training at University of Vermont College of Medicine after obtaining a Master of Science Degree in Nutritional Science at the University of Washington. She completed her preliminary General Surgery and Urology Residency training at Massachusetts General Hospital.

She currently is the Director of the Kidney Stone Program at Massachusetts General Hospital, Vice Director of the MGH Urology Residency Program, and was chosen to participate in the AUA Leadership Program for 2010-2011. She is also on the Board of Directors for the New England Section of the American Urological Association and the Massachusetts Association of Practicing Urologists. She specializes in adult and pediatric kidney and bladder stone disease: ESWL (extracorporeal shockwave lithotripsy), ureteroscopy, laser lithotripsy, complex stone procedures, diagnostic evaluation of ureteral and renal urothelial abnormalities, laparoscopic removal of benign non functioning kidneys, and percutaneous stone procedures (PCNL).

Clinical Interests:

Treats:

Locations

Mass General Urology
165 Cambridge St.
7th Floor
Boston, MA 02114
Phone: 857-238-3838

Medical Education

  • MD, University of Vermont College of Medicine
  • Residency, Massachusetts General Hospital*****

American Board Certifications

  • Urology, American Board of Urology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Research is focused on technological innovations in kidney stone disease.

Obtained a CIMIT grant to work with computer engineers in the development of a GPS guidance system for stone surgery.

here is a focus on the use of the BackStop polymer in stone disease to prevent retropulsion of stones when treating them with a laser. This thermosensitive polymer was trialed in animals by us and now with the FDA approval in place, will be utilized in patients to enhance kidney stone surgery.

Other areas of focus are on infectious complications from stone disease and their prevention as well as the natural history of stone disease as seen through stone composition over time in recurrent stone formers.

Publications

Reviews: Comments and Ratings